Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $19.2900 (-6.95%) ($18.8400 - $20.9500) on Wed. Jul. 29, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.22% (three month average) | RSI | 23 | Latest Price | $19.2900(-6.95%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.9% a day on average for past five trading days. | Weekly Trend | TGTX declines -5.1% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(63%) ARKG(58%) IWO(56%) ARKK(55%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.11% in a week (0% probabilities). VIXM(-34%) VXX(-32%) UUP(-17%) DRIV(-4%) XLC(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.11% (StdDev 6.22%) | Hourly BBV | 0 () | Intraday Trend | -7% | | | |
|
Resistance Level | $21.92 | 5 Day Moving Average | $20.75(-7.04%) | 10 Day Moving Average | $21.58(-10.61%) | 20 Day Moving Average | $21.92(-12%) | To recent high | -20.1% | To recent low | 71.3% | Market Cap | $2.443b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |